1 — Item 32 of 32 <q > rt é L<) id i+ ENE)
2 “Question Id: 14919 LS 4 Mark Pars Next ieee ® Lab a Notes Calculator Reverse Color —Text Zoom &.
= Bisphosphonates are eliminated by the kidney and should be used with caution in patients with

5 chronic kidney disease, but do not have substantial nephrotoxicity.

6

7 (Choice B) Bisphosphonates decrease bone resorption, thus lowering serum calcium levels.

: They are sometimes used in the treatment of severe hypercalcemia (eg, hypercalcemia of

10 malignancy).

i1

12 (Choice D) Venous thromboembolism is a recognized complication of selective estrogen

= receptor modulators (eg, raloxifene), but these medications do not often cause esophagitis.

15 Bisphosphonates do not appreciably increase the risk of thromboembolism.

16

17 (Choice E) Vitamin B,, deficiency can be seen in long-term proton pump inhibitor (eg,

omeprazole) therapy, possibly due to decreased acid-dependent cleavage of vitamin B,. from

+ 20 dietary proteins. Although proton pump inhibitors may be taken by patients with

» 21
a bisphosphonate-induced esophagitis, bisphosphonates do not affect vitamin B,, metabolism.
» 23
5 MA Educational objective:
ca Medication-induced esophagitis is a common adverse effect of bisphosphonates.
26
7 Bisphosphonates are also associated with increased risk of osteonecrosis of the jaw and
7 28 atypical femoral fractures.

Block Time Elapse
Tutor End Block

